Four years of monitoring clinical use of Ofev (nintedanib) by people with idiopathic pulmonary fibrosis (IPF) has found no new…
Articles by Forest Ray PhD
Treatment has commenced in a Phase 2 clinical trial investigating the safety and effectiveness of NP-120…
The European Research Council (ERC) has awarded the Institute for Research in Biomedicine (IRB) Barcelona a €150,000 ($176,000)…
Conditions affecting the heart, stomach, and esophagus occur more frequently in patients whose diagnosis of idiopathic pulmonary fibrosis (IPF)…
Biognosys and Boehringer Ingelheim are working together to expand the use of cutting-edge technologies for large-scale protein analysis in…
Failure of organs other than the lungs can be a predictor of mortality risk in people hospitalized due to acute…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure…
IPF Cell Atlas, the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF), is now available to…
Algernon Pharmaceuticals has begun screening patients for its Phase 2 clinical trial investigating its repurposed compound NP-120 (ifenprodil)…
Single lung transplant patients with idiopathic pulmonary fibrosis (IPF) have a higher risk of developing lung cancer, according to…